Where did Professor Khan receive his medical education?

Professor Khan graduated from Guy's Hospital Medical School in 1994.

What are Professor Khan's qualifications in Gastroenterology and Hepatology?

He is a Fellow of the Royal College of Physicians and has completed specialist training in Gastroenterology and Hepatology.

What are some of the key roles Professor Khan has held in his career?

He has served as a Course Director, Director of Admissions and Inclusivity, Deputy Admissions Tutor, Director of Clinical Studies, and Consultant Physician in various hospitals and institutions.

What are some of the conditions Professor Khan specializes in treating?

Professor Khan specializes in treating conditions like liver function tests, abdominal pain, viral hepatitis, fatty liver, liver cancer, and provides procedures like FibroScan and Endoscopy.

What is Professor Khan's experience in teaching and education?

Professor Khan is a certified Royal College of Physicians Educator, has taught undergraduate and postgraduate students, and has received several Teaching Awards.

Where does Professor Khan currently practice as a consultant physician?

Professor Khan is a Consultant Physician at BMI The Clementine Churchill Hospital, St Mary's Hospital - Lindo Wing, The London Clinic, St Mary’s and Hammersmith Hospitals, and Imperial College London Healthcare NHS Trust.

What is Professor Khan's academic affiliation?

Professor Khan is a Professor of Practice (Hepatology) at Imperial College London.

Has Professor Khan received any awards or recognition for his work?

Professor Khan has received several Teaching Awards at Imperial College London for his contributions to medical education.

Does Professor Khan speak any languages besides English?

Professor Khan is fluent in Urdu and Hindi.

Professor Shahid Khan

Gastroenterologist

Consults at:

The Clementine Churchill Hospital - part of Circle Health Group

Surgeries

N/A

Experience

30+ years

About

ist accreditation in General Internal Medicine. He qualified from Guy's Hospital Medical School in 1994 and underwent house-officer posts at Greenwich District Hospital and Guy's Hospital. Professor Khan trained as a senior house officer at Hammersmith, Charing Cross, St Thomas', and West Middlesex Hospitals. He then went on to become a Specialist Registrar in Gastroenterology.

Between 1999 and 2002 he was a Clinical Research Fellow at Imperial College London. He was awarded a PhD from the University of London in 2003 for his studies in liver cancer. Professor Khan completed his senior gastroenterology and specialist Hepatology training at St Mary's Hospital and University College Hospital in London. Professor Khan became a Fellow of the Royal College of Physicians in 2010.

He has since been running a general hepatology and gastroenterology service and founded a dedicated clinic for decompensated cirrhotic patients and also for primary liver cancer. He is also the academic and clinical lead for liver cancer and is a designated endoscopy trainer.

Professor Khan is a certified Royal College of Physicians Educator and teaches both undergraduates and postgraduates. He was the Course Director of the Gastroenterology & Hepatology BSc programme at Imperial College London for several years and is currently the Director of Admissions and Inclusivity for Imperial College School of Medicine. He has received several Teaching Awards at Imperial College London. He also speaks Urdu and Hindi fluently.

]

Education

Professor of Practice (Hepatology), Imperial College London
Course Director of the Gastroenterology and Hepatology BSc programme, Imperial College London
Director of Clinical Studies, St Mary’s Hospital Campus (2013 – 2016)
Deputy Admissions Tutor, Imperial Medical School (2012 - present)

Experience

More than 30 years of experience
Consultant Physician, BMI The Clementine Churchill Hospital (present)
Consultant Physician, St Mary's Hospital - Lindo Wing (present)
Consultant Physician, The London Clinic (present)
Consultant Physician, St Mary’s and Hammersmith Hospitals
Consultant Physician, Imperial College London Healthcare NHS Trust

Awards

Banales J, Marin J, Lamarca A, Rodrigues P, Khan SA, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Rev Gastroenterol Hepatol. 2020 Jun 30. doi: 10.1038/s41575-020-0310-z.
Pericleous M and Khan SA. Epidemiology of HPB Malignancy in the Elderly. EJSO 2020; (in press)
Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD and Khan SA. Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020. 72(1):95-103. doi: 10.1016/j.jhep.2019.09.007.
Dumenci OE, Abellona MR U, Khan SA, Holmes E, Taylor-Robinson SD. Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction. J Hepat Carcinoma 2020; 7: 1-9.
Yousaf A, Kim J, Eliahoo J, Taylor-Robinson SD and Khan SA. Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-analysis. J Clin Exp Hepatology 2019; J Clin Exp Hepatol. 2019 Nov-Dec;9(6):740-748. doi: 10.1016/j.jceh.2019.08.001. Epub 2019 Aug 19.PMID: 31889756
Khan SA, Genus T, Morement H, Murphy A, Rous B, Tataru B. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma – Letter to the Editor. J Hepatology 2019; 71:1261-1262
Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and Risk Factors. Liver Int 2019. DOI 10.1111/liv.14095
Wadsworth CA, Dixon PH, Taylor-Robinson SD, Kim JU, Zabron AA, Wong JH, Chapman MH, McKay SC, Spalding DR, Wasan HS, Pereira SP, Thomas HC, Whittaker JC, Williamson C and Khan SA. Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a risk factor for Cholangiocarcinoma. J Clin Exp Hep 2019;9(2):171-175. doi: 10.1016/j.jceh.2018.06.521.
Mukherjee SK, Toledano MB, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PloS One 2019;14(4):e0212779. doi: 10.1371
Howell J, Atkinson SR, 1, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer 2019; 116: 56-66.
Appleby RN, Moghul I, Khan SA, Yee M, Manousou P, Dew T, Walters JRF. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: a prospective observational study. PloS One 2019; 25;14(1):e0211348. doi: 10.1371/journal.pone.0211348
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nature Rev Clin Oncol 2018 15(2):95-111. doi: 10.1038/nrclinonc.2017.157..
Shabeer LL and Khan SA. Medical Students' Perception of Undergraduate Hepatology Teaching In The UK - A National Survey. Annual General Meeting of the British-Society-of-Gastroenterology. Gut 2018. BMJ Publishing Group. 67: A278-A278 (Conference Abstract).
Khan SA, McClements S, Reccia I, Evans J, Pai M and Sharma R. The Next Generation of Hepatocellular Cancer Experts – What do they think? Hepatic Onc 2017: 3(4), 213–215.
Carruthers J, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP: Nationwide trends in non-alcoholic steatohepatitis in patients with and without diabetes between 2004 and 2014 in England. Diab Res Clin Prac 2017; 132:102-107.
Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan SA, Fowell A, McPherson S, Newsome PN, Oben J, Jeremy Tomlinson J, Tsochatzis E. Frontline Gastroenterology 2017;8:252–259.
Liu NJ, Chapman R, Lin Y, Bentham A, Tyreman M, Philips N, Khan SA, Molly M. Stevens. Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. Nanoscale 2016; 8(23):11834-9.
Howell J, Khan SA, Knapp S, Thursz MR, Sharma R. The clinical role of circulating free tumour DNA in gastrointestinal malignancy. Transl Res. 2016; pii: S1931-5244(16)30461-3.
Howell J, Khan SA. The Role of miRNAs in Cholangiocarcinoma. Hepat Oncol 2016: 3(2):167-180.
Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T. ESMO Clinical Practice Guidelines On behalf of the ESMO Guidelines Working Group: Buliary Tract Cancer. Ann Oncol. 2016;27(s5):v28-v37.
International Webinar on the Management of Hepatocellular Carcinoma for Bayer in the COVID Era (2020)
British Society of Gastroenterology Committee for update of the UK guidelines on the Management of Cholangiocarcinoma (2020)
Plenary Lecture at BASL: What’s New in Cholangiocarcinoma (2019) ...

Hospitals

FAQs

Professor Khan is a highly regarded Gastroenterologist and Hepatologist specializing in liver diseases, including liver cancer and cirrhosis.

Professor Shahid Khan

About

Education

Experience

Awards

Hospitals

FAQs

What is Professor Shahid Khan's area of expertise?

Where did Professor Khan receive his medical education?

What are Professor Khan's qualifications in Gastroenterology and Hepatology?

What are some of the key roles Professor Khan has held in his career?

What are some of the conditions Professor Khan specializes in treating?

What is Professor Khan's experience in teaching and education?

Where does Professor Khan currently practice as a consultant physician?

What is Professor Khan's academic affiliation?

Has Professor Khan received any awards or recognition for his work?

Does Professor Khan speak any languages besides English?

About

Education

Experience

Awards

Hospitals